News Breaks |
|
|
| November 6, 2012 |
| 19:25 EDT |  | MDT | Medtronic finds biventricular pacing may offer significant clinical advantage
Medtronic announced interim findings from the BLOCK HF trial, which show that biventricular pacing may offer a significant clinical advantage and improved patient outcomes over conventional right ventricular pacing among patients with left ventricular systolic dysfunction and atrioventricular block who are indicated for a pacemaker. Presented as a late-breaking clinical trial at the American Heart Association's 2012 Scientific Sessions, BLOCK HF shows a 27% relative risk reduction in the composite of death and healthcare utilization visits requiring intravenous heart failure therapy among this patient population. The CRT devices used in the BLOCK HF trial are not approved by the FDA for the patient population studied at this time. |
|
|
News For MDT From The Last 14 Days Check below for free stories on MDT the last two weeks. |
|
|
| May 16, 2013 |
| 13:32 EDT |  | MDT | Medtronic volatility flat into Q4 and outlook
 Subscribe for More Information |
|
| 10:03 EDT |  | MDT | On The Fly: Analyst Downgrade Summary
Subscribe for More Information |
|
| 06:32 EDT | | MDT | Medtronic downgraded to Neutral from Outperform at Credit Suisse
Subscribe for More Information |
|
| May 10, 2013 |
| 15:49 EDT | | MDT | Medtronic defibrillators demonstrate success of shock avoidance
Subscribe for More Information |
|
| May 8, 2013 |
| 07:38 EDT |  | MDT | BofA/Merrill's medical tech analyst hold an analyst/industry conference call
Subscribe for More Information |
|
| May 6, 2013 |
| 09:19 EDT | | MDT | Medtronic receives FDA approval for newest cardiac devices
Medtronic announced FDA approval and U.S. launch of its newest cardiac devices: the Viva portfolio of cardiac resynchronization therapy with defibrillation, or CRT-D, devices, and the Evera portfolio of implantable cardioverter-defibrillators. |
|
|
|
|
|
